Table 2.
The points of each study according to the MINORS-score. The maximum score is 16
| Criteria | 1 A clearly stated aim |
2 Inclusion of consecutive patients |
3 Prospective collection of data |
4 Endpoints appropriate to the aim of the study |
5 Unbiased assessment of the study endpoint |
6 Follow up period appropriate to the aim of the study |
7 Loss to follow up less than 5% |
8 Prospective calculation of study size |
Finalized MINORS score |
|---|---|---|---|---|---|---|---|---|---|
| Jain et al. 2020 [22] | 1 | 2 | 0 | 2 | 0 | 2 | 2 | 0 | 9/16 |
| Elgohary et al. 2016 [13] | 1 | 1 | 1 | 1 | 0 | 2 | 2 | 0 | 8/16 |
| Koh et al. 2019 [26] | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 6/16 |
| Massoud 2017 [44] | 1 | 0 | 2 | 0 | 0 | 2 | 2 | 0 | 7/16 |
| Kaul et al. 2020 [23] | 2 | 1 | 0 | 1 | 0 | 2 | 2 | 0 | 8/16 |
| Guclu et al. 2016 [18] | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 5/16 |
| Sadek et al. 2015 [59] | 2 | 0 | 2 | 2 | 1 | 2 | 2 | 0 | 11/16 |
| Seker et al. 2016 [61] | 2 | 2 | 0 | 2 | 0 | 1 | 0 | 0 | 7/16 |
| Khiami et al. 2013 [25] | 2 | 2 | 0 | 1 | 1 | 2 | 0 | 0 | 8/16 |
| Pavan Kumar et al. 2013 [55] | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 0 | 9/16 |
| Ozan et al. 2017 [52] | 2 | 0 | 0 | 1 | 0 | 2 | 2 | 0 | 7/16 |
| Lins et al. 2013 [33] | 1 | 1 | 1 | 2 | 0 | 2 | 2 | 0 | 9/16 |
| El Shazly et al. 2014 [11] | 2 | 1 | 2 | 2 | 0 | 2 | 0 | 1 | 10/16 |
| Bąkowski et al. 2020 [5] | 1 | 0 | 0 | 1 | 0 | 2 | 2 | 2 | 8/16 |
| Maffulli et al. 2014 [36] | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 12/16 |
| Song et al. 2018 [63] | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 9/16 |
| Dumbre et al. 2014 [10] | 1 | 1 | 1 | 2 | 0 | 2 | 2 | 0 | 9/16 |
| Maffulli et al. 2018 [38] | 1 | 1 | 2 | 2 | 0 | 2 | 2 | 0 | 10/16 |
| Bansal et al. 2021 [6] | 2 | 1 | 2 | 2 | 0 | 1 | 2 | 0 | 10/16 |
| Gedam et al. 2016 [15] | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 4/16 |
| Li et al. 2021 [31] | 1 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 7/16 |
| Bai et al. 2019 [4] | 1 | 1 | 0 | 2 | 0 | 2 | 0 | 0 | 6/16 |
| Maffuli et al. 2013 [37] | 2 | 1 | 2 | 2 | 1 | 2 | 2 | 0 | 12/16 |
| Nilsson Helander et al. 2008 [47] | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 0 | 13/16 |
| El Shewy et al. 2009 [12] | 0 | 2 | 1 | 1 | 0 | 2 | 2 | 0 | 8/16 |
| Sarzaeem et al. 2012 [60] | 1 | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 11/16 |
| Takao et al. 2003 [65] | 0 | 2 | 0 | 1 | 0 | 2 | 2 | 0 | 7/16 |
| Muliera et al. 2003 [45] | 1 | 0 | 0 | 1 | 0 | 2 | 2 | 0 | 6/16 |
| Lin et al. 2019 [32] | 1 | 2 | 0 | 2 | 0 | 2 | 2 | 0 | 9/16 |
| Werken et al. 1983 [67] | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2/16 |
| Gunaratne et al. 2021 [19] | 1 | 2 | 0 | 1 | 0 | 2 | 0 | 0 | 6/16 |
| Nilsson et al. 2022 [46] | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 9/16 |
| Nordenholm, Nilsson et al. 2022 [49] | 2 | 1 | 0 | 2 | 0 | 2 | 2 | 0 | 9/16 |
| Nordenholm, Senorski et al. 2022 [50] | 2 | 1 | 2 | 2 | 1 | 2 | 2 | 0 | 12/16 |
| Raju et al. 2022 [57] | 1 | 2 | 0 | 1 | 0 | 2 | 2 | 0 | 8/16 |
| Tsukada et al. 2022 [69] | 1 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | 7/16 |